Evaluating the cost-effectiveness of the Prostate Cancer Patient Empowerment Program
Canadian Urological Association Journal · 28.08.2025 · 19 (12)
DOI: 10.5489/cuaj.9222 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Urological Association Journal, online erschienen am 28.08.2025. Verfasst von Alexandra Nuyens und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Community Health and Epidemiology, Dalhousie University, Halifax, NS, Canada. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
The aim of this study was to evaluate the cost-effectiveness of the Prostate Cancer Patient Empowerment Program (PC-PEP), a six-month comprehensive intervention designed to enhance psychological well-being and reduce healthcare expenditures among prostate cancer patients.
Methods
In a crossover randomized clinical trial of 128 men aged 50–82 years scheduled for curative prostate cancer surgery or radiotherapy (± hormone treatment), 66 men received the PC-PEP intervention immediately, while 62 were randomized to a waitlist-control arm and received standard care for six months before receiving PC-PEP. The intervention included daily activities targeting physical fitness, pelvic floor training, stress management, intimacy, social support, and dietary guidance. Cost-effectiveness was assessed from a healthcare payer perspective using billing data from Nova Scotia’s Medical Services Insurance (MSI) and self-reported outcomes. Incremental cost-effectiveness ratios (ICERs) and cost-effectiveness acceptability curves (CEACs) were calculated using bootstrapped samples. Psychological distress was assessed with the Kessler Psychological Distress Scale (K10), while quality-adjusted life years (QALYs) were estimated from SF-6D utility scores.
Results
PC-PEP resulted in cost savings of $411.53 CAD per patient at six months, with a 30% reduction in clinically significant psychological distress and a QALY gain of 0.013. At 12 months, savings increased to $660.89 CAD per patient, preventing 31% of distress cases and yielding a QALY gain of 0.034. These outcomes demonstrate that PC-PEP is a dominant intervention, achieving both improved clinical outcomes and reduced healthcare expenditures.
Conclusions
PC-PEP is a dominant, cost-effective strategy that significantly improves psychological well-being while lowering healthcare costs. Early implementation following prostate cancer diagnosis is strongly recommended to maximize both clinical and economic benefits.
Autor:innen und Institutionen
- Department of Community Health and Epidemiology, Dalhousie University, Halifax, NS, Canada.
- Department of Urology, Dalhousie University, Halifax, NS, Canada.
- Department of Radiation Oncology, Dalhousie University, Halifax, NS, Canada.
- School of Health Administration, Faculty of Health, Dalhousie University, Halifax, NS, Canada.
- Research Innovation and Discovery, Nova Scotia Health, Halifax, NS, Canada.
Zitieren
APA
Nuyens, A., Ilie, G., Rendon, R. A., Mason, R. J., Hajizadeh, M., Koto, P. S., Foley, M., Kokorovic, A., Patil, N., Bowes, D., Bailly, G., Wilke, D., MacDonald, C., & Rutledge, R. D. H. (2025). Evaluating the cost-effectiveness of the Prostate Cancer Patient Empowerment Program. Canadian Urological Association Journal, 19(12). https://doi.org/10.5489/cuaj.9222
Vancouver
Nuyens A, Ilie G, Rendon RA, Mason RJ, Hajizadeh M, Koto PS, et al. Evaluating the cost-effectiveness of the Prostate Cancer Patient Empowerment Program. Canadian Urological Association Journal. 2025;19(12). doi:10.5489/cuaj.9222
BibTeX
@article{Nuyens2025,
author = {Nuyens, Alexandra and Ilie, Gabriela and Rendon, Ricardo A and Mason, Ross J and Hajizadeh, Mohammad and Koto, Prosper Senyo and Foley, Martha and Kokorovic, Andrea and Patil, Nikhilesh and Bowes, David and Bailly, Greg and Wilke, Derek and MacDonald, Cody and Rutledge, Robert David Harold},
title = {Evaluating the cost-effectiveness of the Prostate Cancer Patient Empowerment Program},
journal = {Canadian Urological Association Journal},
year = {2025},
volume = {19},
number = {12},
doi = {10.5489/cuaj.9222}
}
EUVIMED